Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call Transcript
Good day, everyone, and welcome to the Leap Therapeutics DKN-01 Clinical Investigator Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I will now turn the call over to Dr. Cynthia Sirard, Chief Medical Officer of Leap. Please begin.
Thank you, operator. Welcome, and thank you to those of you joining us today for an update on Leap Therapeutics DKN-01 development program. I'm Cynthia Sirard, and with me today are Dr. Samuel Klempner, an Associate Professor at Harvard Medical School, who leads the gastric and esophageal cancer program at Massachusetts General Hospital Cancer Center; J. Baum, Vice President and Head of Translational Medicine at Leap; and Douglas Onsi, President and Chief Executive Officer at Leap.
This call is being accompanied by a slide deck, so I will ask you to please turn to our forward-looking statements on Slide 2. I would like to remind you that any statements made during
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |